Clinical information: crd_992 - valved grafts pas, patient site id: (b)(6).It was reported that on (b)(6) 2023, a 25mm sjm masters series valsalva aortic valved graft was selected for implant.During the procedure, the patient experienced an aortic tick requiring hemostasis control via reperfusion.The patient also went into ventricular fibrillation and required defibrillation.No concomitant cardiac procedures were performed.There were no intraprocedural device deficiencies noted.Post procedure on (b)(6) 2023, the patient had increased post-operative bleeding and required a re-thoracotomy and mediastinal revision.Blood clots were removed, residual blood was observed in the pericardial sac, the left pleural cavity was aspirated, and the patient was given a blood transfusion and plasma.Two bleeding sites were found and treated.Patient had anemia in the form of decreased hemoglobin and hematocrit due to bleeding.Further blood transfusions were given on (b)(6), (b)(6), and (b)(6) 2023.These events were life-threatening and required prolonged hospitalization.The patient was discharged from the hospital on (b)(6) 2023.
|
An event of ventricular fibrillation requiring defibrillation, increased post-operative bleeding was reported.A returned device assessment could not be performed as the device remains implanted and was not returned for analysis.Based on the information received, the cause of the reported incident could not be conclusively determined.The device history record was reviewed to ensure that each manufacturing and inspection operation was performed and the product met all specifications.There is no indication of a product quality issue with respect to labeling design or manufacturing of the device.
|